OBJECTIVE: We compared neurodevelopmental outcomes at 18 to 22 months' corrected age of infants born with extremely low birth weight at an estimated gestational age of <25 weeks during 2 periods: 1999-2001 (epoch 1) and 2002-2004 (epoch 2). PATIENTS AND METHODS: We conducted a multicenter, retrospective analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Perinatal and neonatal variables and outcomes were compared between epochs. Neurodevelopmental outcomes at 18 to 22 months' corrected age were evaluated with neurologic exams and Bayley Scales of Infant Development II. Logistic regression analyses determined the independent risk of epoch for adverse outcomes. RESULTS: Infant survival was similar between epochs (epoch 1, 35.4%, vs epoch 2, 32.3%; P = .09). A total of 411 of 452 surviving infants in epoch 1 and 405 of 438 surviving infants in epoch 2 were evaluated at 18 to 22 months' corrected age. Cesarean delivery (P = .03), surgery for patent ductus arteriosus (P = .004), and late sepsis (P = .01) were more common in epoch 2, but postnatal steroid use was dramatically reduced (63.5% vs 32.8%; P < .0001). Adverse outcomes at 18 to 22 months' corrected age were common in both epochs. Moderate-to-severe cerebral palsy was diagnosed in 11.1% of surviving infants in epoch 1 and 14.9% in epoch 2 (adjusted odds ratio [OR]: 1.52 [95% confidence interval (CI): 0.86-2.71]; P = .15), the Mental Developmental Index was <70 in 44.9% in epoch 1 and 51% in epoch 2 (OR: 1.30 [95% CI: 0.91-1.87]; P = .15), and neurodevelopmental impairment was diagnosed in 50.1% of surviving infants in epoch 1 and 58.7% in epoch 2 (OR: 1.4 [95% CI: 0.98-2.04]; P = .07). CONCLUSIONS: Early-childhood outcomes for infants born at <25 weeks' estimated gestational age were unchanged between the 2 periods.
OBJECTIVE: We compared neurodevelopmental outcomes at 18 to 22 months' corrected age of infants born with extremely low birth weight at an estimated gestational age of <25 weeks during 2 periods: 1999-2001 (epoch 1) and 2002-2004 (epoch 2). PATIENTS AND METHODS: We conducted a multicenter, retrospective analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Perinatal and neonatal variables and outcomes were compared between epochs. Neurodevelopmental outcomes at 18 to 22 months' corrected age were evaluated with neurologic exams and Bayley Scales of Infant Development II. Logistic regression analyses determined the independent risk of epoch for adverse outcomes. RESULTS: Infant survival was similar between epochs (epoch 1, 35.4%, vs epoch 2, 32.3%; P = .09). A total of 411 of 452 surviving infants in epoch 1 and 405 of 438 surviving infants in epoch 2 were evaluated at 18 to 22 months' corrected age. Cesarean delivery (P = .03), surgery for patent ductus arteriosus (P = .004), and late sepsis (P = .01) were more common in epoch 2, but postnatal steroid use was dramatically reduced (63.5% vs 32.8%; P < .0001). Adverse outcomes at 18 to 22 months' corrected age were common in both epochs. Moderate-to-severe cerebral palsy was diagnosed in 11.1% of surviving infants in epoch 1 and 14.9% in epoch 2 (adjusted odds ratio [OR]: 1.52 [95% confidence interval (CI): 0.86-2.71]; P = .15), the Mental Developmental Index was <70 in 44.9% in epoch 1 and 51% in epoch 2 (OR: 1.30 [95% CI: 0.91-1.87]; P = .15), and neurodevelopmental impairment was diagnosed in 50.1% of surviving infants in epoch 1 and 58.7% in epoch 2 (OR: 1.4 [95% CI: 0.98-2.04]; P = .07). CONCLUSIONS: Early-childhood outcomes for infants born at <25 weeks' estimated gestational age were unchanged between the 2 periods.
Authors: Jerold F Lucey; Cherise A Rowan; Patricia Shiono; Andrew R Wilkinson; Sarah Kilpatrick; Nathaniel R Payne; Jeffrey Horbar; Joseph Carpenter; Jeannette Rogowski; Roger F Soll Journal: Pediatrics Date: 2004-06 Impact factor: 7.124
Authors: Laura R Ment; Betty Vohr; Walter Allan; Karol H Katz; Karen C Schneider; Michael Westerveld; Charles C Duncan; Robert W Makuch Journal: JAMA Date: 2003-02-12 Impact factor: 56.272
Authors: Waldemar A Carlo; Scott A McDonald; Avroy A Fanaroff; Betty R Vohr; Barbara J Stoll; Richard A Ehrenkranz; William W Andrews; Dennis Wallace; Abhik Das; Edward F Bell; Michele C Walsh; Abbot R Laptook; Seetha Shankaran; Brenda B Poindexter; Ellen C Hale; Nancy S Newman; Alexis S Davis; Kurt Schibler; Kathleen A Kennedy; Pablo J Sánchez; Krisa P Van Meurs; Ronald N Goldberg; Kristi L Watterberg; Roger G Faix; Ivan D Frantz; Rosemary D Higgins Journal: JAMA Date: 2011-12-07 Impact factor: 56.272
Authors: Rachel G Hirschberger; Karl C K Kuban; Thomas M O'Shea; Robert M Joseph; Tim Heeren; Laurie M Douglass; Carl E Stafstrom; Hernan Jara; Jean A Frazier; Deborah Hirtz; Julie V Rollins; Nigel Paneth Journal: Pediatr Neurol Date: 2017-11-13 Impact factor: 3.372
Authors: Noelle Younge; Ricki F Goldstein; Carla M Bann; Susan R Hintz; Ravi M Patel; P Brian Smith; Edward F Bell; Matthew A Rysavy; Andrea F Duncan; Betty R Vohr; Abhik Das; Ronald N Goldberg; Rosemary D Higgins; C Michael Cotten Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: Laurel A Slaughter; Eliana Bonfante-Mejia; Susan R Hintz; Igor Dvorchik; Nehal A Parikh Journal: Neonatology Date: 2016-04-07 Impact factor: 4.035
Authors: Nazakat M Merchant; Denis V Azzopardi; Ahmed F Hawwa; James C McElnay; Benita Middleton; J Arendt; Tomoki Arichi; Pierre Gressens; A David Edwards Journal: Br J Clin Pharmacol Date: 2013-11 Impact factor: 4.335
Authors: Amanda Benavides; Andrew Metzger; Alexander Tereshchenko; Amy Conrad; Edward F Bell; John Spencer; Shannon Ross-Sheehy; Michael Georgieff; Vince Magnotta; Peg Nopoulos Journal: Pediatr Res Date: 2018-09-19 Impact factor: 3.756